Edward Lanphier
Edward Lanphier has been intimately involved in the biotechnology industry since its inception over twenty years ago and is a leading authority on the industry.
In 1981, Mr. Lanphier published the first commercial analysis of the then nascent biotechnology industry. He authored the first "Genetic Engineering Industry Directory" as well as studies detailing the potential commercial significance of this emerging science including reports entitled Advances in Biotechnology Commercialization and Monoclonal Antibody Market Opportunities. In 1982 he joined Eli Lilly & Co. in the Strategic Business Planning group responsible for biotechnology product acquisitions. This began a career that has seen Edward Lanphier start, build or take public several leading biotechnology companies including Celtrix Pharmaceuticals, Somatix Therapy Corporation and Sangamo BioSciences.
As a biotechnology industry veteran, Edward Lanphier will share his perspectives on the role of biotechnology (and other emerging technologies such as the sequencing of the human genome, bioinformatics, gene therapy, and genetically modified transgenic plants) in our society and our economy. Additionally he can address the importance of research and development in the pharmaceutical and agricultural industries and the need for public policies to support these efforts.
Edward Lanphier is a frequent speaker at a wide range of biotechnology industry conferences. In the past two years he has made presentations at some of the countries premier financial conferences including the Hambrecht & Quist Health Care Conference; the BancBoston Robertson, Stephens Medical Conference; and the U.S. Bancorp Piper Jaffray Medical Technologies Conference.
Additionally Edward Lanphier has given detailed commercial presentations on gene therapy, regulation of gene expression, development of transgenic plants, novel anti-viral therapeutics, and DNA diagnostics/pharmacogenomics.
Edward Lanphier is the founder, President and Chief Executive Officer of Sangamo BioSciences, Inc. Sangamo is a publicly held biotechnology company (NASDAQ: SGMO) focused on the development of novel transcription factors for the regulation of human, plant and microbial genes. The company has signed collaborative research agreements with Pfizer, SmithKline Beecham, Millennium Pharmaceuticals, Zeneca, Berlex Biosciences, Bayer AG, GlaxoWellcome, DuPont Pharmaceuticals, Japan Tobacco, Hoffmann-LaRoche and Genset.
Edward Lanphier has twenty years of experience in the pharmaceutical and biotechnology industry. From 1992 to 1997, he was executive vice president, commercial development and chief financial officer (1996-97) at Somatix Therapy Corporation, a leading gene therapy company. Prior to Somatix, Mr. Lanphier was president and chief executive officer of BioGrowth, Inc., which merged with Celtrix Laboratories to form Celtrix Pharmaceuticals, Inc. in 1991. Mr. Lanphier was also the vice president of corporate development at Synergen, Inc. and before joining Synergen in 1984, he was with Eli Lilly and Company in Strategic Business Planning - Biotechnology.
Mr. Lanphier is a member of the Biotechnology Industry Organization (BIO) board of directors.
-
Dan Nye
Dan Nye, chief executive officer of the professional social network site LinkedIn, told Fox Business ... -
Larry Page
Larry Page was Google's founding CEO and grew the company to more than 200 employees and profitability ... -
Eric Schmidt
Chairman of the Board and Chief Executive Officer , Google ...
- News
- Videos
- Products
-
Unfortunately, there are no News Items currently available for this speaker.
Fee Information: Booking Fees to hire speakers and celebrities are determined based on a number factors and often change without notice. Some factors include: speakers schedule, length of presentation, location of event, market conditions, availability and interest. Fee Ranges listed on this website are intended to serve only as a guideline. For the most current celebrity fees or to check availability, please contact a booking agent.
Please Note: All American Speakers Bureau acts only as an entertainment broker/producer for corporate functions, private engagements and special events. All American Speakers Bureau does not claim or represent itself as the exclusive booking agency, business manager, publicist, speakers bureau or management for Edward Lanphier or any artists or celebrities on this website.
All American Speakers is a "buyers agent" and exclusively represents talent buyers looking to secure celebrities and speakers for personal appearances, speaking engagements, corporate entertainment, private events, public relations campaigns, promotions, commercials and product endorsements.
Profiles listed on this website are provided as a resource to our clients, which are meeting and event planners and other buyers of talent in order to provide them with the widest variety and selection of available talent. For more information on how we work and what makes us unique, please read about the All American Speakers Bureau Advantage.
Due to the volume of emails and calls we receive, we can no longer respond to inquiries related to any of the following:
- Schedules of upcoming public appearances
- Contact info for artists or requests to forward messages.
- Artist's TV, stage or film projects or representation
- Requests for artists to donate items for auctions, etc.
- Media requests for print, radio or TV interviews.
- Non-paying or expenses only fundraisers.
- Any inquiry not related to hiring talent for paid engagements
Related Tags: Find More Information on booking Edward Lanphier for appearances, speaking engagements, endorsements/spokesperson, appearance fees, booking agency contact info, biography of Edward Lanphier, Contact an artist booking talent agent find a speakers bureau that can book Edward Lanphier, speaker booking agency for Edward Lanphier, list of similar speakers and celebrities for hire, what is the cost to book a top 10 motivational speaker, musician, comedian or famous athlete.
Copyright © 2012-2013All American Speakers LLC - All rights reserved.
